Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) – Pipeline Review, H2 2017’, provides in depth analysis on Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Genetic Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders under development targeting Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

Celgene Corp

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

IRBM Science Park SpA

Italfarmaco SpA

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Mirati Therapeutics Inc

Sigma-Tau SpA

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Overview 8

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 17

Products under Development by Universities/Institutes 25

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Therapeutics Assessment 27

Assessment by Mechanism of Action 27

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Companies Involved in Therapeutics Development 32

4SC AG 32

Celgene Corp 32

Chipscreen Biosciences Ltd 33

Curis Inc 34

HitGen LTD 35

IRBM Science Park SpA 35

Italfarmaco SpA 36

Medivir AB 36

MEI Pharma Inc 37

Merck & Co Inc 37

Mirati Therapeutics Inc 38

Sigma-Tau SpA 39

Syndax Pharmaceuticals Inc 39

Zhejiang Hisun Pharmaceutical Co Ltd 40

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Drug Profiles 41

4SC-202 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ACY-1035 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ACY-1071 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

ACY-738 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ACY-957 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

crocetin - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CS-3158 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

CUDC-907 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

entinostat - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

givinostat - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

HG-3001 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

largazole - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

mocetinostat - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

pracinostat - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

RCY-1305 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

RCY-1497 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

RCY-1992 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

remetinostat - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

resminostat - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

ST-3595 - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

tucidinostat - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

vorinostat - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Dormant Products 114

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Discontinued Products 117

Histone Deacetylase 1 (HDAC1 or EC

3.5.1.98) - Product Development Milestones 118

Featured News & Press Releases 118

Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 118

Jul 19, 2017: Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer's Disease at the Alzheimer's Association International Conference 119

Jul 11, 2017: Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 119

Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 120

Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 121

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 122

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 122

May 17, 2017: Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Advanced Melanoma 123

May 16, 2017: Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies 124

Apr 20, 2017: Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 125

Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 125

Apr 11, 2017: New mechanistic insights into 4SC-202’s epigenetic mode of action 126

Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 127

Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup 128

Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 128

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15

Number of Products under Development by Indications, H2 2017 (Contd..4), H2 2017 16

Number of Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 18

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 23

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 24

Number of Products under Investigation by Universities/Institutes, H2 2017 25

Products under Investigation by Universities/Institutes, H2 2017 26

Number of Products by Stage and Mechanism of Actions, H2 2017 27

Number of Products by Stage and Route of Administration, H2 2017 29

Number of Products by Stage and Molecule Type, H2 2017 31

Pipeline by 4SC AG, H2 2017 32

Pipeline by Celgene Corp, H2 2017 33

Pipeline by Chipscreen Biosciences Ltd, H2 2017 34

Pipeline by Curis Inc, H2 2017 35

Pipeline by HitGen LTD, H2 2017 35

Pipeline by IRBM Science Park SpA, H2 2017 36

Pipeline by Italfarmaco SpA, H2 2017 36

Pipeline by Medivir AB, H2 2017 37

Pipeline by MEI Pharma Inc, H2 2017 37

Pipeline by Merck & Co Inc, H2 2017 38

Pipeline by Mirati Therapeutics Inc, H2 2017 39

Pipeline by Sigma-Tau SpA, H2 2017 39

Pipeline by Syndax Pharmaceuticals Inc, H2 2017 40

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 40

Dormant Products, H2 2017 114

Dormant Products, H2 2017 (Contd..1), H2 2017 115

Dormant Products, H2 2017 (Contd..2), H2 2017 116

Discontinued Products, H2 2017 117

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 27

Number of Products by Routes of Administration, H2 2017 28

Number of Products by Stage and Routes of Administration, H2 2017 28

Number of Products by Molecule Types, H2 2017 30

Number of Products by Stage and Molecule Types, H2 2017 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports